Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study.
Alzheimer's
PET
amyloid
dementia
memory clinic population
mild cognitive impairment
subjective cognitive decline
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
17 Jun 2022
17 Jun 2022
Historique:
revised:
11
03
2022
received:
16
09
2021
accepted:
29
04
2022
entrez:
18
6
2022
pubmed:
19
6
2022
medline:
19
6
2022
Statut:
aheadofprint
Résumé
AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort. Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice. A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms. The features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : The AMYPAD project is funded by the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU)
ID : 115952
Informations de copyright
© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189-a006189. https://doi.org/10.1101/cshperspect.a006189
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55(3):306-319. https://doi.org/10.1002/ana.20009
Grundman M, Pontecorvo MJ, Salloway SP, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27(1):4-15. https://doi.org/10.1097/WAD.0b013e318279d02a
Boccardi M, Altomare D, Ferrari C, et al. Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET with [18F]-Florbetapir (INDIA-FBP) Study. JAMA Neurol. 2016;73(12):1417-1424. https://doi.org/10.1001/jamaneurol.2016.3751
Zwan MD, Bouwman FH, Konijnenberg E, et al. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimer's Res Ther. 2017;9(1):2. https://doi.org/10.1186/s13195-016-0228-4
Ceccaldi M, Jonveaux T, Verger A, et al. Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: a Naturalistic Study. Alzheimer's Dement. 2018;14(3):293-305. https://doi.org/10.1016/j.jalz.2017.09.009
Brendel M, Schnabel J, Schönecker S, et al. Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. Eur J Nucl Med Mol Imaging. 2017;44(13):2239-2248. https://doi.org/10.1007/s00259-017-3832-z
Carswell CJ, Win Z, Muckle K, et al. Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients. J Neurol Neurosurg Psychiatry. 2017;89(3):294-299. jnnp-2017-316194. https://doi.org/10.1136/jnnp-2017-316194
De Wilde A, Van Der Flier WM, Pelkmans W, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 2018;75(9):1062-1070. https://doi.org/10.1001/jamaneurol.2018.1346
Leuzy A, Savitcheva I, Chiotis K, et al. Clinical impact of [18 F]flutemetamol PET among memory clinic patients with an unclear diagnosis. Eur J Nucl Med Mol Imaging. 2019;46(6):1276-1286. https://doi.org/10.1007/S00259-019-04297-5
Chiotis K, Saint-Aubert L, Boccardi M, et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:214-227. https://doi.org/10.1016/j.neurobiolaging.2016.07.012
Frisoni GB, Barkhof F, Altomare D, et al. AMYPAD diagnostic and patient management study: rationale and design. Alzheimer's Dement. 2019;15(3):388-399. https://doi.org/10.1016/j.jalz.2018.09.003
Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's Dement. 2014;10(6):844-852. https://doi.org/10.1016/j.jalz.2014.01.001
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7(3):270-279. https://doi.org/10.1016/j.jalz.2011.03.008
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7(3):263-269. https://doi.org/10.1016/j.jalz.2011.03.005
EQ-5D-5L. EQ-5D. https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/. Accessed November 25, 2020.
Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727-1736. https://doi.org/10.1007/s11136-011-9903-x
ICECAP-O. University of Birmingham. https://www.birmingham.ac.uk/research/activity/mds/projects/HaPS/HE/ICECAP/ICECAP-O/index.aspx. Accessed November 25, 2020.
Perry-Duxbury M, van Exel J, Brouwer W, et al. A validation study of the ICECAP-O in informal carers of people with dementia from eight European countries. Qual Life Res. 2020;29(1):237-251. https://doi.org/10.1007/s11136-019-02317-3
Brief-COPE. NovoPsych Psychometrics. https://novopsych.com.au/assessments/brief-cope/. Accessed November 25, 2020.
Carver CS. You want to measure coping but your protocol's too long: consider the brief COPE. Int J Behav Med. 1997;4(1):92-100. https://doi.org/10.1207/s15327558ijbm0401_6
Eisenberg SA, Shen BJ, Schwarz ER, Mallon S. Avoidant coping moderates the association between anxiety and patient-rated physical functioning in heart failure patients. J Behav Med. 2012;35(3):253-261. https://doi.org/10.1007/s10865-011-9358-0
Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA - J Am Med Assoc. 2019;321(13):1286-1294. https://doi.org/10.1001/jama.2019.2000
Saghaei M, Saghaei S. Implementation of an open-source customizable minimization program for allocation of patients to parallel groups in clinical trials. J Biomed Sci Eng. 2011;4(11):734-739. https://doi.org/10.4236/jbise.2011.411090
Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimer's Dis. 2018;62(3):1091-1111. https://doi.org/10.3233/JAD-170850
Verhage F. Intelligence and Age: Study With Dutch People Aged 12-77. Assen van Gorcum; 1964.